Optically active cantharidin analogues possessing selective inhibitory activity on Ser/Thr protein phosphatase 2B (calcineurin): Implications for the binding mode

Bioorganic and Medicinal Chemistry

Volumn 13, Issue 17, 2005, Pages 5164-5170

  Baba, Yoshiyasu ^a   Hirukawa, Nozomu ^a   Sodeoka, Mikiko ^a,b  

^a TOHOKU UNIVERSITY   (Japan)

^b INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

Calcineurin; Cantharidin; Inhibitor; Optically active; PP2B

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CANTHARIDIN; NORCANTHARIDIN; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN SERINE THREONINE KINASE;

ARTICLE; BINDING KINETICS; CRYSTAL STRUCTURE; DERIVATIZATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HYDROPHOBICITY; STEREOCHEMISTRY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUBSTITUTION REACTION; X RAY ANALYSIS;

BINDING SITES; CALCINEURIN; CANTHARIDIN; CIRCULAR DICHROISM; ENZYME INHIBITORS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; SPECTROPHOTOMETRY, ULTRAVIOLET; STEREOISOMERISM;

EID: 22844451947     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.05.013     Document Type: Article

References (37)

1. G.S. Wang J. Ethnopharmacol. 26 1989 147 162
2. A.H. McCluskey, and J.A. Sakoff Mini Rev. Med. Chem. 1 2001 43 55
3. Y.-M. Li, and J.E. Casida Proc. Natl. Acad. Sci. U.S.A. 89 1992 11867 11870
4. Y.-M. Li, C. MacKintosh, and J.E. Casida Biochem. Pharmacol. 46 1993 1435 1443
5. R.E. Honkanen FEBS Lett. 330 1993 283 286 and references therein
6. A. McCluskey, C. Taylor, and R.J. Quinn Bioorg. Med. Chem. Lett. 6 1996 1025 1028
7. A. Enz, G. Zenke, and E. Pombo-Villar Bioorg. Med. Chem. Lett. 7 1997 2513 2518
8. A. McCluskey, M.A. Keane, L.-M. Mudgee, A.T.R. Sim, J. Sakoff, and R.J. Quinn Eur. J. Med. Chem. 35 2000 957 964
9. A. McCluskey, M.C. Bowyer, E. Collins, A.T.R. Sim, J.A. Sakoff, and M.L. Baldwin Bioorg. Med. Chem. Lett. 10 2000 1687 1690
10. A. McCluskey, C. Walkom, M.C. Bowyer, S.P. Ackland, E. Gardiner, and J.A. Sakoff Bioorg. Med. Chem. Lett. 11 2001 2941 2946
11. A. McCluskey, M.A. Keane, C.C. Walkom, M.C. Bowyer, A.T.R. Sim, D.J. Young, and J.A. Sakoff Bioorg. Med. Chem. Lett. 12 2002 391 393
12. J.A. Sakoff, S.P. Ackland, M.L. Baldwin, M.A. Keane, and A. McCluskey Invest. New Drugs 20 2002 1 11
13. A. McCluskey, T.R. Sim, and J.A. Sakoff J. Med. Chem. 45 2002 1151 1175
14. M.E. Hart, R. Chamberlin, C. Wakom, J.A. Sakoff, and A. McCluskey Bioorg. Med. Chem. Lett. 14 2004 1969 1973
15. J.E. Sheppeck II, C.-M. Gausss, and A.R. Chamberlin Bioorg. Med. Chem. 5 1997 1739 1750 and references cited therein
16. Y. Baba, N. Hirukawa, N. Tanohira, and M. Sodeoka J. Am. Chem. Soc 125 2003 9740 9749
17. Preliminary SAR results, see: M. Sodeoka, Y. Baba, S. Kobayashi, and N. Hirukawa Bioorg. Med. Chem. Lett. 7 1997 1833 1836
18. J.H. Tatlock, M.A. Linton, X.J. Hou, C.R. Kissinger, L.A. Pelletier, R.E. Showalter, A. Tempczyk, and J.E. Villafranca Bioorg. Med. Chem. Lett. 7 1997 1007 1012
19. M.J. Tocci, D.A. Matkovich, K.A. Collier, P. Kwok, F.J. Dumont, S. Lin, S. Degudicibus, J.J. Siekierka, J. Chin, and N.I. Hutchison J. Immunol. 143 1989 718 726
20. C. Randak, T. Brabletz, M. Hergenrother, I. Sobotta, and E. Serfling EMBO J 9 1990 2529 9536
21. W.M. Flanagan, B. Corthesy, R.J. Bram, and G.R. Crabtree Nature 352 1991 803 807
22. P.G. McCaffrey, B.A. Perrino, T.R. Soderling, and A. Rao J. Biol. Chem. 268 1993 3747 3752
23. L.N. Tsao, C. Neville, A. Musaro, K.J.A. McCullagh, and N. Rosenthal Nat. Med. 6 2000 2 3
24. J. Liu, J.D. Farmer Jr., W.S. Lane, J. Friedman, I. Weissman, and S.L. Schreiber Cell 66 1991 807 815
25. S.L. Schreiber, M.W. Albers, and E. Brown J. Acc. Chem. Res. 26 1993 412 420 and references cited therein
26. For other types of PP2B inhibitors, see: R. Baumgrass, M. Weiwad, F. Erdmann, J.O. Liu, D. Wunderlich, S. Grabley, and G. Fisher J. Biol. Chem. 276 2001 47914 47921 and references cited therein
27. For details of our strategy for developing phosphatase inhibitors, see: M. Sodeoka, R. Sampe, S. Kojima, Y. Baba, T. Usui, K. Ueda, and H. Osada J. Med. Chem. 44 2001 3216 3222
28. T. Usui, S. Kojima, S. Kidokoro, K. Ueda, H. Osada, and M. Sodeoka Chem. Biol. 8 2001 1209 1220
29. M. Sodeoka, and Y. Baba J. Synth. Org. Chem. Jpn. 59 2001 1095 1102
30. C.-M. Gausss, J.E. Sheppeck II, A.C. Nairn, and A.R. Chamberlin Bioorg. Med. Chem. 5 1997 1751 1773
31. Imide derivatives of norcantharidin, which were prepared by the reaction of norcantharidin with various optically active amino acids, have been reported, but no chirality exists in the oxabicyclo[2.2.1]heptane skeleton of these compounds. See Ref. 3e
32. S.K.-H. Swanson, T. Born, L.D. Zydowsky, H. Cho, H.Y. Chang, C. Walsh, and F. Rusnak Proc. Natl. Acad. Sci. U.S.A. 89 1992 3741 3745
33. C.R. Kissinger, H.E. Perge, D.R. Knighton, C.T. Lewis, L.A. Pelletier, A. Tempczyk, V.J. Kalish, K.D. Tucker, R.E. Showalter, E.W. Moomaw, L.N. Gastinel, N. Habuka, X. Chen, F. Maldonado, J.E. Barker, R. Bacquet, and J.E. Villafranca Nature 378 1995 641 644
34. J.P. Griffith, J.L. Kim, E.E. Kim, M.D. Sintchak, J.A. Thomson, M.J. Fitzgibbon, M.A. Fleming, P.R. Caron, K. Hsiao, and M.A. Navia Cell 82 1995 507 522
35. J. Goldberg, H.B. Huang, Y.G. Kwon, P. Greengard, A.C. Nairn, and J. Kuriyan Nature 376 1995 745 753
36. Crystal structure of PP1-calyculin complex, see: A. Kita, S. Matsunaga, A. Takai, H. Kataiwa, T. Wakimoto, N. Fusetani, M. Isobe, and K. Miki Structure 10 2002 715 724
37. V. Theurillat-Moritz, and P. Vogel Tetrahedron: Asymmetry 7 1996 3163 3168